A Modified SCID Mouse Model of HIV Infection with Utility for Testing Anti-HIV Therapies

AIDS Research and Human Retroviruses

Volumn 19, Issue 10, 2003, Pages 901-908

  Pincus, Seth H ^a,b,e   Fang, Hua ^a,d   Wilkinson, Royce A ^a   Olson, William C ^c   Marcotte, Tamera K ^a  

^a MONTANA STATE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIV HLTH SCI C   (United States)

^c A Subsidiary of Lantheus Holdings   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

^e The Research Institute for Children at Children's Hospital New Orleans   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; IMMUNOGLOBULIN G2; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; ZIDOVUDINE;

ANIMAL MODEL; ANTIVIRAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCID MOUSE; T LYMPHOCYTE; TUMOR CELL; VIRUS INFECTION;

ANIMALS; ANTI-HIV AGENTS; ANTIBODIES, VIRAL; CD4 IMMUNOADHESINS; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; SPLEEN; TUMOR CELLS, CULTURED;

EID: 0242301650     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203322493076     Document Type: Review

References (43)

1. Bonyhadi ML, Rabin L, Salimi S, et al.: HIV induces thymus depletion in vivo. Nature 1993;363:728-732.
2. + T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science 1993;260:689-691.
3. Wetherall NT: The development of HIV-1 p24 antigenemia in the athymic "nude" mouse. In: Animal Models of AIDS (Schellekens H and Horzinek MC, eds.). Elsevier Science Publishers, Amsterdam, 1990.
4. Sato A, Kodama M, Abe K. et al.: A simple and rapid method for preliminary evaluation of in vivo efficacy of anti-HIV compounds in mice. Antiviral Res 1995;27:151-163.
5. Hollingshead M, Roberson J, Decker W, et al.: In vivo drug screening applications of HIV-infected cells cultured within hollow fibers in two physiologic compartments of mice. Antiviral Res 1995; 28:265-279.
6. Lapenta C, Fais S, Rizza P, et al.: U937-SCID mouse xenografts: A new model for acute in vivo HIV-1 infection suitable to test antiviral strategies. Antiviral Res. 1997;36:81-90.
7. Sanhadji K, Grave L, Touraine JL, et al.: Gene transfer of anti-gp41 antibody and CD4 immunoadhesin strongly reduces the HIV-1 load in humanized severe combined immunodeficient mice. AIDS 2000;14:2813-2822.
8. Quenelle DC, Keith KA, Dunleavy KE, et al.: Evaluation of anti-AIDS drugs in conventional mice implanted with a permeable membrane device containing human T cells infected with HIV. Antiviral Res 1997;35:123-129.
9. Pincus SH, Fang H, Wilkinson RA, et al : In vivo efficacy of anti-gp41, but not anti-gp120, immunotoxins in a mouse model of HIV infection. J Immunol 2003;170:2236-2241.
10. Allaway GP, Davis-Bruno KL, Beaudry GA, et al.: Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV-1 isolates. AIDS Res Hum Retroviruses 1995; 11:533-539.
11. Pincus SH, Wehrly K, and Chesebro B: Treatment of HIV tissue culture infection with monoclonal antibody-ricin A chain conjugates. J Immunol 1989;142:3070-3075.
12. Pincus SH, Cole RL, Hersh EM, et al.: In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. J Immunol 1991;146:4315-4324.
13. Pincus SH and McClure J: Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of HIV. Proc Natl Acad Sci USA 1993;90:332-336.
14. + cell line H9. AIDS Res Hum Retroviruses 1989;5:253-255.
15. Adachi A, Gendelman HE, Koenig S, et al.: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59:284-291.
16. Pincus SH and Wehrly K: AZT demonstrates anti-HIV-1 activity in persistently infected cell lines: Implications for combination chemotherapy and immunotherapy. J Infect Dis 1990;162: 1233-1238.
17. + T-cell clone (PM1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 1995;69:3712-3720.
18. Chesebro B, Wehrly K, Nishio J, and Perryman S: Macrophage-tropic HIV isolates from different patients exhibit unusual V3 envelope sequence homogeneity in comparison with T-cell-tropic isolates: Definition of critical amino acids involved in cell tropism. J Virol 1992;66:6547-6554.
19. Platt EJ, Wehrly K, Kuhmann SR, Chesebro B, and Kabat D: Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage-tropic isolates of HIV-1. J Virol 1998;72:2855-2864.
20. Pincus SH, Wehrly K, Cole R, et al.: In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on the HIV-1 envelope glycoprotein gp160. AIDS Res Hum Retrovirus 1996;12: 1041-1051.
21. Pincus SH, Marcotte TK, Forsyth BM, and Fang H: In vivo testing of anti-HIV immunotoxins. In: Immunotoxin Methods and Protocols (Hall WA, ed.). Humana Press, Totowa, NJ, 2001, pp. 277-294.
22. Jacobson JM, Colman N, Ostrow NA, et al.: Passive immunotherapy in the treatment of advanced human immunodeficiency virus infection. J Infect Dis 1993;168:298-305.
23. Shultz LD, Schweitzer PA, Christianson SW, et al.: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995;154:180-191.
24. LaCasse RA, Follis KE, Trahey M, et al.: Fusion-competent vaccines: broad neutralization of primary isolates of HIV. Science 1999;283:357-362.
25. Browning J, Horner JW, Pettoello-Mantovani M, et al.: Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc Natl Acad Sci USA 1997;94:14637-14641.
26. McCune JM, Namikawa R, Shih C-C, Rabin L, and Kaneshima H: Suppression of HIV infection in AZT-treated SCID-hu mice. Science 1990;247:564-566.
27. Namikawa R, Kaneshima H, Lieberman M, Weissman IL, and McCune JM: Infection of the SCID-hu mouse by HIV-1. Science 1988;242:1684-1686.
28. Mosier DE: Small animal models for AIDS research. Lab Anim Sci 1996;46:257-265.
29. Mosier DE, Gulizia RJ, MacIsaac PD, Corey L, and Greenberg PD: Resistance to HIV-1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. Proc Natl Acad Sci USA 1993;90:2443-2447.
30. Zhang C, Cui Y, Houston S, and Chang L-J: Protective immunity to HIV-1 in SCID/beige mice reconstituted with peripheral blood lymphocytes of exposed but uninfected individuals. Proc Natl Acad Sci USA 1996;93:14720-14725.
31. Aldrovandi GM and Zack JA: Replication and pathogenicity of HIV-1 accessory gene mutants in SCID-hu mice. J Virol 1996; 70:1505-1511.
32. Gulizia RJ, Collman RG, Levy JA, Trono D, and Mosier DE: Deletion of nef slows but does not prevent CD4-positive T-cell depletion in human immunodeficiency virus type 1-infected human-PBL-SCID mice. J Virol 1997;71:4161-4164.
33. Goldstein H, PettoelloMantovani M, Bera TK, Pastan I, and Berger EA: Chimeric toxins targeted to the HIV-1 envelope glycoprotein augment the in vivo activity of combination antiretroviral therapy in thy/liv-SCID-Hu mice. J Infect Dis 2000;181:921-926.
34. Hesselton RAM, Greiner DL, Mordes JP, et al.: High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to HIV-1 infection in NOD/LtSz-scid/scid mice. J Infect Dis 1995;172:974-982.
35. Gaudin M-C, Allaway GP, Olson WC, et al.: CD4-IgG2 protects Hu-PBL-SCID mice against challenge by primary HIV-1 isolates. J Virol 1998;72:3475-3478.
36. + T cells passaged into SCID mice leads to selection of chronically infected cells through a massive fas-mediated autocrine suicide of uninfected cells. Cell Death Differ 2000;1:37-47.
37. Ghetie MA, Gordon BE, Podar EM, and Vitetta ES: Effect of sublethal irradiation of SCID mice on growth of B-cell lymphoma xenografts and on efficacy of chemotherapy and/or immunotoxin. Lab Animal Sci 1996;46:305-309.
38. Chesebro B and Wehrly K: Development of a sensitive quantitative focal assay for human immunodeficiency virus infectivity. J Virol 1988;62:3779-3788.
39. Pincus SH, Wehrly K, and Chesebro B: Use of a focal infectivity assay for testing susceptibility of HIV to antiviral agents. BioTechniques 1991;10:336-342.
40. Gaudin M-C, Parren PW, Weir R, et al.: Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat Med 1997;3:1389-1393.
41. Poignard P, Sabbe R, Picchio GR, et al.: Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999;10:431-438.
42. Andrus L, Prince AM, Bernal I, et al.: Passive immunization with a human immunodeficiency virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice: Isolation of a neutralization escape variant. J Infect Dis 1998;177:889-897.
43. Okamoto Y, Eda Y, Ogura A, et al.: In SCID-hu mice, passive transfer of a humanized antibody prevents infection and atrophic change of medulla in human thymic implant due to intravenous inoculation of primary HIV-1 isolate. J Immunol 1998;160:69-76.